Untitled-2 Untitled-2 Untitled-2
Healthcare Innovation
1315 Capital invests in exceptional healthcare teams and companies

1315 Capital is a private investment firm that provides expansion and growth capital to commercial-stage specialty pharmaceutical, medical technology, and healthcare service companies. We target markets where high-quality management teams can rapidly scale platform companies into large and important businesses that positively impact patients, physicians, and the broader healthcare system.


The 1315 Capital investment team combines financial and business development expertise with deep industry knowledge to support the growth of our portfolio companies.

Learn More


1315 Capital employs a unique Operating Team model to navigate diligence, drive decisions, and achieve premium exits.

Learn More


1315 Capital has a deep network that it leverages for management talent, advisors, deal sourcing, diligence, and boards roles.

Learn More

News & Events
Ampersand Capital Partners and 1315 Capital to Acquire Genoptix
January 30, 2017
Encore Dermatology Inc. Announces Launch of TridesilonTM (desonide) Cream, 0.05%
January 17, 2017
Two FDA chiefs, other luminaries to address CED Life Science Conference
January 13, 2017

Dermatology company committed to delivering innovative prescription therapies and medical devices to dermatologists.

Cost-containment service company focused on reprocessing single-use medical devices.

Special needs equipment and supply company that serves the pediatric and adult special needs population.

Specialty pharmaceutical company focused on nutraceutical and women’s health products.

Medical device company focused on the orthopedic oncology market.

Generic Levitra - active ingredient: Vardenafil. Presented at dosages of 20, 40 mg, and compatible with the alcohol version. The effect occurs after an average of 30-40 minutes after administration. Read more: